

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
07 September 2023 (07.09.2023)



(10) International Publication Number
WO 2023/168296 A3

(51) International Patent Classification:

A61K 31/395 (2006.01) A61K 31/015 (2006.01)
A61K 31/404 (2006.01) A61K 31/33 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2023/063521

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(22) International Filing Date:

01 March 2023 (01.03.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(88) Date of publication of the international search report:

26 October 2023 (26.10.2023)

(30) Priority Data:

63/315,472 01 March 2022 (01.03.2022) US
63/327,345 04 April 2022 (04.04.2022) US

(71) Applicant: ADARX PHARMACEUTICALS, INC.

[US/US]; 5871 Oberlin Drive, Suite 200, San Diego, CA
92121 (US).

(72) Inventors: NUMA, Mehdi, Michel Djamel; c/o Adarx

Pharmaceuticals, Inc., 5871 Oberlin Drive, Suite 200, San
Diego, CA 92121 (US). LI, Zhen; c/o Adarx Pharmaceuti-
cals, Inc., 5871 Oberlin Drive, Suite 200, San Diego, CA
92121 (US). ZHU, Rui; c/o Adarx Pharmaceuticals, Inc.,
5871 Oberlin Drive, Suite 200, San Diego, CA 92121 (US).
CHIRUTA, Chandramouli; c/o Adarx Pharmaceuticals,
Inc., 5871 Oberlin Drive, Suite 200, San Diego, CA 92121
(US).

(74) Agent: HSI, Jeffrey, D. et al.; Wolf, Greenfield & Sacks,

P.C., 600 Atlantic Avenue, Boston, MA 02210-2206 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA,
ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: CBI LIGAND CONJUGATED COMPOUNDS AND USES THEREOF

(57) Abstract: Provided herein are CB₁ ligand-containing compounds, methods of delivering said compounds, and methods of treating diseases, disorders, and symptoms (e.g., central nervous system diseases, disorders, and symptoms) in a subject using said compounds.

WO 2023/168296 A3